Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

World Journal of Urology

Volumn 32, Issue 2, 2014, Pages 431-435

  Bolton, D M ^a   Ta, A ^a   Bagnato, M ^b   Muller, D ^b   Lawrentschuk, N L ^a   Severi, G ^b   Syme, R R ^b   Giles, G G ^b  

^a AUSTIN HEALTH   (Australia)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

Biochemical recurrence; Disease specific mortality; Prostate cancer; Radical prostatectomy; Whole of population

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; AUSTRALIA; BLOOD; CANCER GRADING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FACTUAL DATABASE; HUMAN; MALE; MEDICAL RECORD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK; SURVIVAL RATE; TIME; TUMOR RECURRENCE;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; TIME FACTORS; VICTORIA;

EID: 84897091488     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1125-0     Document Type: Article

References (28)

1. Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916.
2. Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517-523.
3. Porter CR, Kodama K, Gibbons RP et al (2006) 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176: 569-574.
4. Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J Urol 172: 910-914.
5. Boorjian SA, Karnes RJ, Crispen PL et al (2010) The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 183: 1003-1009.
6. Lodde M, Harel F, Lacombe L et al (2008) Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World J Urol 26: 225-229.
7. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 5(281): 1591-1597.
8. Ward JF, Blute ML, Slezak J (2003) The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872-1876.
9. Isbarn H, Wanner M, Salomon G et al (2010) Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 106: 37-43.
10. Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 10(27): 4300-4305.
11. Antonarakis ES, Feng Z, Trock BJ et al (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109: 32-39.
12. Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
13. Freedland SJ, Humphreys EB, Mangold LA (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176: 1404-1408.
14. Caire AA, Sun L, Ode O et al (2009) Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology 74: 643-647.
15. Amling CL, Blute ML, Bergstralh EJ et al (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164: 101-105.
16. Loeb S, Feng Z, Ross A et al (2012) Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol 186: 500-505.
17. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101.
18. Johansson J-E, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291: 2713-2719.
19. Bolton D, Severi G, Millar JL et al (2009) A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000. Aust N Z J Public Health 33: 527-533.
20. Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 18(299): 2760-2769.
21. Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185: 869-875.
22. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 126-131.
23. van den Bergh RCN, Vasarainen H, van der Poel HG et al (2010) Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 105: 956-962.
24. Walz J, Chun FKH, Klein EA et al (2009) Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 181: 601-607 (discussion 7-8).
25. Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8: 162-200.
26. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71.
27. Ahove DA, Hoffman KE, Hu JC et al (2009) Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?-implications for a risk-adapted follow-up strategy. Urology 76: 1201-1205.
28. Tollefson MK, Blute ML, Rangel LJ et al (2011) Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol 184: 925-929.